Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Non-Current Liabilities (2023 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $66.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 16.52% to $66.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.2 million, a 16.52% decrease, with the full-year FY2025 number at $66.2 million, down 16.52% from a year prior.
  • Total Non-Current Liabilities was $66.2 million for Q4 2025 at Day One Biopharmaceuticals, up from $62.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $79.3 million in Q4 2024 to a low of $29.5 million in Q4 2023.
  • A 3-year average of $58.1 million and a median of $59.8 million in 2025 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 168.66% in 2024, then decreased 16.52% in 2025.
  • Day One Biopharmaceuticals' Total Non-Current Liabilities stood at $29.5 million in 2023, then soared by 168.66% to $79.3 million in 2024, then fell by 16.52% to $66.2 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Total Non-Current Liabilities are $66.2 million (Q4 2025), $62.2 million (Q3 2025), and $57.4 million (Q2 2025).